The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Immune checkpoint blockade upfront in older AML and HR-MDS
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the first large randomized trial (NCT02775903) of azacitidine with or without immune checkpoint blockade in older unfit acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). While the study did not reach its primary endpoint, Dr Zeidan reveals the important insights that can be taken away. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
